Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
$1.51
+6.3%		$1.62
$0.90
▼
$5.20
$21.42M1.0391,166 shs46,573 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.40
+35.3%		$0.49
$0.20
▼
$1.55
$16.51M1.4627.52 million shs78.42 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,712.46%
NextTrip, Inc. stock logo
NTRP
NextTrip
+6.34%+7.09%+3.42%-26.34%-61.68%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
+35.33%+81.41%+73.07%-58.43%-65.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.60
$0.60
$0.00
▼
$0.80
$35.79M1.7515,632 shsN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
$1.51
+6.3%		$1.62
$0.90
▼
$5.20
$21.42M1.0391,166 shs46,573 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.40
+35.3%		$0.49
$0.20
▼
$1.55
$16.51M1.4627.52 million shs78.42 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%0.00%0.00%+1,712.46%
NextTrip, Inc. stock logo
NTRP
NextTrip
+6.34%+7.09%+3.42%-26.34%-61.68%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
+35.33%+81.41%+73.07%-58.43%-65.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
2.00
Hold$7.75413.25% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.33
Hold$9.002,155.07% Upside

Current Analyst Ratings Breakdown

Latest ADXS, NTRP, and PDSB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
NextTrip, Inc. stock logo
NTRP
NextTrip
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$7.50 ➝ $7.75
9/11/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/1/2026
NextTrip, Inc. stock logo
NTRP
NextTrip
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/26/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/14/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M11.05N/AN/A($2.06) per share-0.29
NextTrip, Inc. stock logo
NTRP
NextTrip
$3.72M6.13N/AN/A$0.42 per share3.60
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.18 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
-$15.91M-$1.41N/AN/AN/A-289.92%-246.48%-105.09%10/21/2026 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$34.50M-$0.64N/AN/AN/AN/A-708.18%-136.50%11/12/2026 (Estimated)

Latest ADXS, NTRP, and PDSB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.13-$0.18-$0.05-$0.18N/AN/A
7/15/2026Q1 2027
NextTrip, Inc. stock logo
NTRP
NextTrip
-$0.22-$0.22N/A-$0.22$1.38 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
0.02
0.61
0.61
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.73
0.57
0.57

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
NextTrip, Inc. stock logo
NTRP
NextTrip
3.81%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
NextTrip, Inc. stock logo
NTRP
NextTrip
40.00%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2059.31 million42.36 millionNot Optionable
NextTrip, Inc. stock logo
NTRP
NextTrip
1215.09 million9.05 millionNo Data
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2055.97 million51.27 millionOptionable

Recent News About These Companies

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
September 14 at 11:59 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pds-biotech-announces-initial-closing-143000980.html
PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board
September 14 at 10:51 AM  |  quiverquant.comQ
FY2026 EPS Estimate for PDS Biotechnology Reduced by Analyst
September 13 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31019684
Stock Traders Buy Large Volume of PDS Biotechnology Call Options (NASDAQ:PDSB)
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013804
PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong
September 8, 2026  |  rttnews.comhttps://www.rttnews.com/3689237/pds-biotech-raises-up-to-22-55m-in-pipe-led-by-dr-patrick-soon-shiong.aspx
PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pds-biotechnology-raises-22-6-142648653.html
PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure
September 8, 2026  |  quiverquant.comQ
PDS Biotech soars as it announces up to $22.55 million financing
September 8, 2026  |  thepharmaletter.comT
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357657/37149/en/pds-biotech-announces-up-to-22-55-million-financing-led-by-dr-patrick-soon-shiong-founder-of-nantworks.html
PDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2026 Financial Results
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69304147-pds-biotechnology-corporation-pds-biotech-reports-second-quarter-2026-financial-results-399.htm
PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss
August 13, 2026  |  quiverquant.comQ
PDS Biotech Reports Second Quarter 2026 Financial Results
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html
PDS Biotechnology Corporation: PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277004-pds-biotechnology-corporation-pds-biotech-announces-strategic-refocus-prioritizing-pds0301-in-metastatic-colorectal-cancer-mcrc-and-partnership-str-399.htm
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pds-biotech-announces-strategic-refocus-122500178.html
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
August 11, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61121031/pds-biotechnology-stock-crashes-strategic-refocus-pivots-to-metastatic-colorectal-cancer-program?utm_source=snapi
PDS Biotechnology Refocuses on PDS0301, Ends Internal Development of PDS0101 Phase 3 Trial
August 11, 2026  |  quiverquant.comQ
PDS Biotechnology Sets 2026 Annual Stockholders Meeting Date
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pds-biotechnology-sets-2026-annual-stockholders-meeting-date?utm_source=marketbeat.com&utm_medium=referral
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
June 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2935180/here-s-why-pds-biotechnology-pdsb-could-be-great-choice-for-a-bottom-fisher?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2935180
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2026 Earnings Call Transcript
May 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/pds-biotechnology-corporation-nasdaqpdsb-q1-2026-earnings-call-transcript-1762056/
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
May 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/pds-biotechnology-q1-2026-earnings-122611518.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.60 0.00 (0.00%)
As of 09/11/2026

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

NextTrip stock logo

NextTrip NASDAQ:NTRP

$1.51 +0.09 (+6.34%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$1.52 +0.01 (+0.66%)
As of 09/14/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextTrip, Inc., through its subsidiaries, engages in the provision of travel technology solutions in the United States. The company offers NXT2.0, a booking engine technology platform, which provides travel distributors access to an inventory. It is also involved in the provision of online leisure travel agency services for booking hotels, flights, and curated vacations. The company was formerly known as Sigma Additive Solutions, Inc. and changed its name to NextTrip, Inc. in March 2024. NextTrip, Inc. is based in Sunrise, Florida.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$0.40 +0.10 (+35.33%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$0.44 +0.05 (+11.50%)
As of 09/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas